What is Virios Therapeutics Financial Strength?
Virios Therapeutics has the Financial Strength Rank of 10. It shows strong financial strength and is unlikely to fall into distressed situations.
Good Sign:
Virios Therapeutics Inc shows strong financial strength.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Virios Therapeutics has no long-term debt (1).
As of today, Virios Therapeutics's Altman Z-Score is 0.00.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Virios Therapeutics's Financial Strength
For the Biotechnology subindustry, Virios Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virios Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virios Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Virios Therapeutics's Financial Strength falls into.
Virios Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Virios Therapeutics's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-1.31 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
Virios Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is
| Virios Therapeutics had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Virios Therapeutics Inc has no debt.
2. Debt to revenue ratio. The lower, the better.
Virios Therapeutics's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Virios Therapeutics has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Virios Therapeutics (Virios Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
44 Milton Avenue, Alpharetta, GA, USA, 30009
Virios Therapeutics Inc is a development-stage biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia. The company is engaged in the development of its product, IMC-1, for people who are suffering from fibromyalgia.
Executives
| William Pridgen |
director |
44 MILTON AVENUE, ALPHARETTA GA 30009 |
| Gregory Scott Duncan |
director, officer: Chief Executive Officer |
44 MILTON AVENUE, ALPHARETTA GA 30009 |
| Richard James Whitley |
director |
UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711 |
| Angela Walsh |
officer: VP of Finance |
44 MILTON AVENUE, ALPHARETTA GA 30009 |
| De La Rosa Abel |
director |
44 MILTON AVENUE, ALPHARETTA GA 30009 |
| John C Thomas |
director |
8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615 |
| David R Keefer |
director |
44 MILTON AVENUE, ALPHARETTA GA 30009 |
| Ralph Grosswald |
officer: Vice President of Operations |
44 MILTON AVENUE, ALPHARETTA GA 30009 |
| Roger Michael Gendreau |
officer: Chief Medical Officer |
44 MILTON AVENUE, ALPHARETTA GA 30009 |
| Richard Alan Burch |
director |
44 MILTON AVENUE, ALPHARETTA GA 30009 |
Virios Therapeutics (Virios Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VIRI has been successfully added to your